Ensera, a contract development and manufacturing organisation focused on injectable drugs, has launched the Ensera alliance network, a group of device and fill-finish specialists meant to make it easier to bring drug-device combination products to market. The network was announced from Dublin on 1 October 2026 and includes SHL Medical, Stevanato Group, Ypsomed, Argonaut Manufacturing Services and American Injectables, according to the company press release.
Key Takeaways
- Ensera launched an alliance network linking device platform providers with fill-finish specialists for combination products.
- The members named are SHL Medical, Stevanato Group and Ypsomed (device platforms), plus Argonaut Manufacturing Services and American Injectables (fill-finish).
- Participation is non-exclusive, members stay independent, and customers can work with each company separately.
- Ensera says it plans to add organisations whose capabilities and standards fit existing members and customer needs.
- The claims about speed and coordination come from the company. No customer results or timelines were disclosed.
What Is the Ensera Alliance Network?
The Ensera alliance network is a structured set of relationships between Ensera and five other companies that each cover a different step of making an injectable combination product. Device platform providers supply the injector or syringe system. Fill-finish specialists put the drug into the device or container under sterile conditions. Ensera positions itself as the CDMO that connects those parts and supports final assembly, labelling and packaging.
A drug-device combination product pairs a medicine with a delivery device, such as an autoinjector or a prefilled syringe, and is regulated as a single product. The US Food and Drug Administration sets out how such products are classified and reviewed, which is one reason programmes involve many suppliers and handovers.
Who Is in the Network?
| Company | Role in the network |
|---|---|
| Ensera | CDMO: commercialisation support, final assembly, labelling, packaging |
| SHL Medical | Device platform provider |
| Stevanato Group | Device platform provider |
| Ypsomed | Device platform provider |
| Argonaut Manufacturing Services | Fill-finish specialist |
| American Injectables | Fill-finish specialist |
Ensera describes itself as a global CDMO that supports commercialisation of injectable drug programmes. The company says it operates across Europe, the United States and Asia, with GMP cleanroom facilities suited to low-to-medium batch volumes. Its service list includes device design and manufacturing, final assembly, labelling, secondary packaging, integrated quality systems and cold chain infrastructure.
Why Combination Product Programmes Slow Down
Bobby O’Connor, Chief Commercial Officer at Ensera, said: “Too many combination product programs are slowed by disconnected suppliers and difficult handovers.” The company says the network brings specialists together in “a more coordinated, responsive model,” as reported by Contract Pharma.
The problem described is a familiar one in the industry. A drug owner may need to select a device platform, find a fill-finish partner, validate the combination, assemble and package it, and then secure commercial supply. Each step often involves a different company with its own quality systems, so delays can build up where responsibilities pass from one party to the next. Demand for these products is also growing, as seen in our coverage of the dual chamber prefilled syringes market and the advanced parenteral drug delivery devices market.
How the Ensera Alliance Network Works
According to the company, the network creates coordinated connections across the combination product supply chain. Pharmaceutical companies can use it to manage device platforms, fill-finish operations, final assembly and packaging, and to move programmes toward commercial supply.
Darren Hieber, VP Alliance Partnerships at Ensera, said: “This network has been built on established relationships, shared experience and practical understanding.” The structure is deliberately flexible. Members remain independent, participation is not exclusive, and customers may contract with any member directly.
What Is Not Yet Known
- Commercial terms: the announcement does not describe pricing, contracts or how work is shared between members.
- Performance data: no figures on time saved, cost reduction or programme counts were published.
- Customers: no pharmaceutical customer using the network has been named.
- Expansion: new members are planned, but no names or dates were given.
What It Means: Our Assessment
In our assessment, the Ensera alliance network is a sensible response to a real coordination problem rather than a new technology. Its value will depend on whether handovers between members become faster and cleaner in practice, which only customer programmes can show. The non-exclusive structure lowers the barrier for drug developers to try it, but it also means the network is a coordination layer, not a single accountable supplier.
For drug developers weighing injectable launches, the news is worth watching alongside wider trends in the CDMO market and in patient-administered care, including the home medical equipment market. Teams considering the model should ask how responsibility is assigned when a problem arises across two members.
Frequently Asked Questions
What is the Ensera alliance network?
It is a network of device platform providers and fill-finish specialists linked with Ensera to streamline commercialisation of drug-device combination products.
Who are the members?
SHL Medical, Stevanato Group and Ypsomed provide device platforms, and Argonaut Manufacturing Services and American Injectables provide fill-finish services.
Is membership exclusive?
No. Participation is non-exclusive, members remain independent, and customers may engage them separately.
What is a drug-device combination product?
It is a product that combines a drug with a delivery device, such as an autoinjector or prefilled syringe, and is regulated as one product.
Will the network expand?
Ensera says it intends to add organisations that align with existing members and customer needs.
How we reported this: information comes from the company press release and trade coverage by Contract Pharma. Claims about speed and coordination are company-reported and not independently verified. Last updated 2 October 2026. This article is for information only and is not medical, investment or business advice.
